COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/219463 |
Resumo: | Coronavirus disease 2019 (COVID-19) was initially characterized due to its impacts on the respiratory system; however, many recent studies have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly affects the brain. COVID-19 can cause neurological complications, probably caused by the induction of a cytokine storm, since there is no evidence of neurotropism by SARS-CoV-2. In line with this, the COVID-19 outbreak could accelerate the progression or affect the clinical outcomes of neuropsychiatric conditions. Thus, we analyzed differential gene expression datasets for clinical samples of COVID-19 patients and identified 171 genes that are associated with the pathophysiology of the following neuropsychiatric disorders: alcohol dependence, autism, bipolar disorder, depression, panic disorder, schizophrenia, and sleep disorder. Several of the genes identified are associated with causing some of these conditions (classified as elite genes). Among these elite genes, 9 were found for schizophrenia, 6 for autism, 3 for depression/major depressive disorder, and 2 for alcohol dependence. The patients with the neuropsychiatric conditions associated with the genes identified may require special attention as COVID-19 can deteriorate or accelerate neurochemical dysfunctions, thereby aggravating clinical outcomes. |
id |
UFRGS-2_407a04d5a42b10a4e23d82ec45d065fb |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/219463 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Quincozes-Santos, AndréRosa, Rafael Lopes daCagnini, Emanuela Fernanda TuretaBobermin, Larissa DanieleOliveira, Markus BergerGuimaraes, Jorge AlmeidaSanti, LucéliaSilva, Walter Orlando Beys da2021-04-06T04:19:33Z20212666-3546http://hdl.handle.net/10183/219463001123077Coronavirus disease 2019 (COVID-19) was initially characterized due to its impacts on the respiratory system; however, many recent studies have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly affects the brain. COVID-19 can cause neurological complications, probably caused by the induction of a cytokine storm, since there is no evidence of neurotropism by SARS-CoV-2. In line with this, the COVID-19 outbreak could accelerate the progression or affect the clinical outcomes of neuropsychiatric conditions. Thus, we analyzed differential gene expression datasets for clinical samples of COVID-19 patients and identified 171 genes that are associated with the pathophysiology of the following neuropsychiatric disorders: alcohol dependence, autism, bipolar disorder, depression, panic disorder, schizophrenia, and sleep disorder. Several of the genes identified are associated with causing some of these conditions (classified as elite genes). Among these elite genes, 9 were found for schizophrenia, 6 for autism, 3 for depression/major depressive disorder, and 2 for alcohol dependence. The patients with the neuropsychiatric conditions associated with the genes identified may require special attention as COVID-19 can deteriorate or accelerate neurochemical dysfunctions, thereby aggravating clinical outcomes.application/pdfengBrain, behavior, & immunity - health. [New York]. Vol. 11 (Feb. 2021), 100196, 5 p.Infecções por coronavirusTranstornos mentaisMarcadores genéticosCOVID-19Neuropsychiatric disordersMolecular markersElite genesNeuroinflammationCOVID-19 impacts the expression of molecular markers associated with neuropsychiatric disordersEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001123077.pdf.txt001123077.pdf.txtExtracted Texttext/plain29739http://www.lume.ufrgs.br/bitstream/10183/219463/2/001123077.pdf.txtb822c81decb4d94ad1de727bfbb5efdeMD52ORIGINAL001123077.pdfTexto completo (inglês)application/pdf1259655http://www.lume.ufrgs.br/bitstream/10183/219463/1/001123077.pdfcd65c26e4bbd3c7f2887eaca24b5bcadMD5110183/2194632023-03-05 03:23:19.273337oai:www.lume.ufrgs.br:10183/219463Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-03-05T06:23:19Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
title |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
spellingShingle |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders Quincozes-Santos, André Infecções por coronavirus Transtornos mentais Marcadores genéticos COVID-19 Neuropsychiatric disorders Molecular markers Elite genes Neuroinflammation |
title_short |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
title_full |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
title_fullStr |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
title_full_unstemmed |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
title_sort |
COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders |
author |
Quincozes-Santos, André |
author_facet |
Quincozes-Santos, André Rosa, Rafael Lopes da Cagnini, Emanuela Fernanda Tureta Bobermin, Larissa Daniele Oliveira, Markus Berger Guimaraes, Jorge Almeida Santi, Lucélia Silva, Walter Orlando Beys da |
author_role |
author |
author2 |
Rosa, Rafael Lopes da Cagnini, Emanuela Fernanda Tureta Bobermin, Larissa Daniele Oliveira, Markus Berger Guimaraes, Jorge Almeida Santi, Lucélia Silva, Walter Orlando Beys da |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Quincozes-Santos, André Rosa, Rafael Lopes da Cagnini, Emanuela Fernanda Tureta Bobermin, Larissa Daniele Oliveira, Markus Berger Guimaraes, Jorge Almeida Santi, Lucélia Silva, Walter Orlando Beys da |
dc.subject.por.fl_str_mv |
Infecções por coronavirus Transtornos mentais Marcadores genéticos |
topic |
Infecções por coronavirus Transtornos mentais Marcadores genéticos COVID-19 Neuropsychiatric disorders Molecular markers Elite genes Neuroinflammation |
dc.subject.eng.fl_str_mv |
COVID-19 Neuropsychiatric disorders Molecular markers Elite genes Neuroinflammation |
description |
Coronavirus disease 2019 (COVID-19) was initially characterized due to its impacts on the respiratory system; however, many recent studies have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly affects the brain. COVID-19 can cause neurological complications, probably caused by the induction of a cytokine storm, since there is no evidence of neurotropism by SARS-CoV-2. In line with this, the COVID-19 outbreak could accelerate the progression or affect the clinical outcomes of neuropsychiatric conditions. Thus, we analyzed differential gene expression datasets for clinical samples of COVID-19 patients and identified 171 genes that are associated with the pathophysiology of the following neuropsychiatric disorders: alcohol dependence, autism, bipolar disorder, depression, panic disorder, schizophrenia, and sleep disorder. Several of the genes identified are associated with causing some of these conditions (classified as elite genes). Among these elite genes, 9 were found for schizophrenia, 6 for autism, 3 for depression/major depressive disorder, and 2 for alcohol dependence. The patients with the neuropsychiatric conditions associated with the genes identified may require special attention as COVID-19 can deteriorate or accelerate neurochemical dysfunctions, thereby aggravating clinical outcomes. |
publishDate |
2021 |
dc.date.accessioned.fl_str_mv |
2021-04-06T04:19:33Z |
dc.date.issued.fl_str_mv |
2021 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/219463 |
dc.identifier.issn.pt_BR.fl_str_mv |
2666-3546 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001123077 |
identifier_str_mv |
2666-3546 001123077 |
url |
http://hdl.handle.net/10183/219463 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Brain, behavior, & immunity - health. [New York]. Vol. 11 (Feb. 2021), 100196, 5 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/219463/2/001123077.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/219463/1/001123077.pdf |
bitstream.checksum.fl_str_mv |
b822c81decb4d94ad1de727bfbb5efde cd65c26e4bbd3c7f2887eaca24b5bcad |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225012167835648 |